Tay Salimullah is the Managing General Partner of Renovamen Advisory LLC, providing consulting and board services to early-stage biotech companies, venture capital, and private equity firms.

He is a former Executive Committee member at AveXis Inc. (later Novartis Gene Therapies), where, as Chief Access Officer, he led global and US access, and reimbursement efforts creating a new commercial model for Zolgensma^®.

With over 20 years of leadership experience in the rare disease and global MedTech sectors, Tay has a proven track record in incubating and scaling innovative, high-value technologies, including cell and gene therapies.

He was instrumental in the strategic commercialisation of Kymriah^® and execution of Zolgensma^®, generating over $5B in cumulative revenue.

Tay’s expertise spans complex regulatory environments, having secured gene therapy approvals in more than 50 markets and helping treat over 4,000 patients globally. His deep knowledge of drug development and cutting-edge R&D ensures the continued relevance of specialty medicines in today’s rapidly evolving landscape.

Tay’s international career includes senior roles at Pfizer and Novartis, covering a range of therapeutic areas, scientific modalities, and diagnostics. His work spans Asia, Africa, Europe and the US, with experience in private equity, global health and the non-profit sectors. Tay holds a BSc in Management Sciences from the University of Brunel, London.